Myriad Genetics, Inc. (0K3W.L)
USD 14.11
(0.53%)
USD 14.11
(0.53%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2022 | 145 Million USD | 57.1% |
| 2021 | 92.3 Million USD | 0.0% |
| 2020 | - USD | -100.0% |
| 2019 | 233.5 Million USD | 0.0% |
| 2018 | 233.5 Million USD | 2410.75% |
| 2017 | 9.3 Million USD | -90.62% |
| 2016 | 99.1 Million USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | -100.0% |
| 1997 | 100 Thousand USD | -75.0% |
| 1996 | 400 Thousand USD | -50.0% |
| 1995 | 800 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q1 | 161.6 Million USD | 11.45% |
| 2023 Q3 | 201.4 Million USD | -1.18% |
| 2023 Q2 | 203.8 Million USD | 26.11% |
| 2022 Q4 | 145 Million USD | 5.61% |
| 2022 Q1 | 89.9 Million USD | -2.6% |
| 2022 Q3 | 137.3 Million USD | 36.35% |
| 2022 Q2 | 100.7 Million USD | 12.01% |
| 2022 FY | 145 Million USD | 57.1% |
| 2021 FY | 92.3 Million USD | 0.0% |
| 2021 Q2 | 200.7 Million USD | -7.68% |
| 2021 Q3 | 93.5 Million USD | -53.41% |
| 2021 Q4 | 92.3 Million USD | -1.28% |
| 2021 Q1 | 217.4 Million USD | -24.78% |
| 2020 Q1 | 294 Million USD | -0.88% |
| 2020 Q3 | 291.7 Million USD | -1.05% |
| 2020 Q2 | 294.8 Million USD | 0.27% |
| 2020 FY | - USD | -100.0% |
| 2020 Q4 | 289 Million USD | -0.93% |
| 2019 Q4 | 296.6 Million USD | -1.33% |
| 2019 Q2 | 233.5 Million USD | -11.35% |
| 2019 FY | 233.5 Million USD | 0.0% |
| 2019 Q1 | 263.4 Million USD | -3.62% |
| 2019 Q3 | 300.6 Million USD | 28.74% |
| 2018 FY | 233.5 Million USD | 2410.75% |
| 2018 Q1 | 69.3 Million USD | 60.42% |
| 2018 Q2 | 9.3 Million USD | -86.58% |
| 2018 Q3 | 258 Million USD | 2674.19% |
| 2018 Q4 | 273.3 Million USD | 5.93% |
| 2017 Q4 | 43.2 Million USD | -41.62% |
| 2017 FY | 9.3 Million USD | -90.62% |
| 2017 Q3 | 74 Million USD | -25.33% |
| 2017 Q2 | 99.1 Million USD | -40.69% |
| 2017 Q1 | 167.1 Million USD | -18.09% |
| 2016 Q2 | - USD | 0.0% |
| 2016 FY | 99.1 Million USD | 0.0% |
| 2016 Q4 | 204 Million USD | 2.41% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q3 | 199.2 Million USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1998 Q3 | - USD | -100.0% |
| 1998 FY | - USD | -100.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q1 | 200 Thousand USD | -33.33% |
| 1998 Q2 | 100 Thousand USD | -50.0% |
| 1997 Q3 | 400 Thousand USD | 0.0% |
| 1997 FY | 100 Thousand USD | -75.0% |
| 1997 Q4 | 300 Thousand USD | -25.0% |
| 1997 Q1 | 500 Thousand USD | -16.67% |
| 1997 Q2 | 400 Thousand USD | -20.0% |
| 1996 Q2 | 800 Thousand USD | -11.11% |
| 1996 Q1 | 900 Thousand USD | 0.0% |
| 1996 FY | 400 Thousand USD | -50.0% |
| 1996 Q4 | 600 Thousand USD | -14.29% |
| 1996 Q3 | 700 Thousand USD | -12.5% |
| 1995 Q4 | 900 Thousand USD | 0.0% |
| 1995 FY | 800 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -296.869% |
| Dynavax Technologies Corporation | 256.91 Million USD | 43.561% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -249.17% |
| Perrigo Company plc | 4.07 Billion USD | 96.44% |
| Illumina, Inc. | 2.26 Billion USD | 93.59% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.585% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -14400.0% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 98.482% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 98.981% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 16.548% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 94.635% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -437.236% |
| Waters Corporation | 2.35 Billion USD | 93.844% |
| Biogen Inc. | 7.33 Billion USD | 98.024% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -280.537% |
| Evolus, Inc. | 126.54 Million USD | -14.583% |
| Adicet Bio, Inc. | 17.7 Million USD | -719.07% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -235.905% |
| bluebird bio, Inc. | 330.32 Million USD | 56.104% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 73.195% |
| FibroGen, Inc. | 170.45 Million USD | 14.934% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 94.698% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -594.304% |
| Homology Medicines, Inc. | 44.05 Million USD | -229.142% |
| Geron Corporation | 85.89 Million USD | -68.803% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 93.953% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 67.42% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -11407.937% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -25.709% |
| Zoetis Inc. | 6.8 Billion USD | 97.869% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -3193.957% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 93.311% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 87.212% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 82.063% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -299.196% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 90.024% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -150.553% |
| Verastem, Inc. | 41.55 Million USD | -248.918% |
| Nektar Therapeutics | 230.4 Million USD | 37.066% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 22.199% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -4616.981% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 89.619% |
| OPKO Health, Inc. | 326.56 Million USD | 55.598% |
| Exelixis, Inc. | 189.94 Million USD | 23.662% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 66.153% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -95926.49% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | -4.762% |
| Imunon, Inc. | 1.13 Million USD | -12627.191% |
| Blueprint Medicines Corporation | 774.12 Million USD | 81.269% |
| Insmed Incorporated | 1.2 Billion USD | 87.957% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 90.328% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -154.44% |
| TG Therapeutics, Inc. | 110.79 Million USD | -30.872% |
| Incyte Corporation | 38.28 Million USD | -278.719% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 83.476% |